A late-stage trial of GlaxoSmithKline’s investigational Crohn’s disease drug failed to benefit patients. The SHIELD-1 study was investigating vercirnon – …
CeramTec expands German production capacity for orthopaedic ceramics
Migraine annual economic and quality-of-life burden in UK
bit.bio expands human heart cell portfolio through myriamed partnership
Phoenix Labs acquires Kent Pharma
Astoriom acquires Sampled’s UK stability storage operations